Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18-70~* ASA class I, II, and III~* undergoing surgery under balanced general anesthesia requiring the use of muscle relaxants throughout the surgery~Exclusion Criteria:~* patients undergoing emergency surgeries~* pregnant patients~* patients with end stage renal disease or chronic kidney disease(GFR less than 60)~* patients with allergy to sugammadex or who had previous complications or side effects from previous sugammadex administration~* patients' refusal~* patients with allergy to recuronium

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 : (NS) (Type: ACTIVE_COMPARATOR): Group 1 Drug combination:~patients receive half of the recommended dose of sugammadex plus dose of neostigmine~1. Sugammadex IV= -1 mg/kg( moderate NMB) or~   * 2 mg/kg (deep NMB)~2. neostigmine IV = 50mcg/kg~3. glycopyrrolate 10 mcg/kg
- Group 2 : (S) (Type: ACTIVE_COMPARATOR): patients receive Full recommended dose of sugammadex~Sugammadex IV= 2mg/kg (Moderate NMB) 4mg/kg ( Deep NMB)

Based on this trial design, predict the completion outcome and termination type (if applicable).